GlassScriptPhysician profile
Mary G Brandon
NPI 1164632287
$1,622.89
in general payments reported to CMS, 2019-2025
10 companies · $461 in 2025
The $461 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2023: $235 · 2024: $688 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.87 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $334.75 | 2021-2025 | Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $276.68 | 2023-2024 | Reblozyl |
| Astellas Pharma US INC | $259.17 | 2024-2025 | Vyloy |
| Gilead Sciences, INC. | $183.99 | 2024-2025 | Trodelvy |
| Fresenius Kabi USA, LLC | $158.87 | 2023-2024 | Stimufend |
| Astrazeneca Pharmaceuticals LP | $134.12 | 2023-2024 | Lynparza, Enhertu |
| Daiichi Sankyo INC. | $124.88 | 2024 | Enhertu |
| Pfizer INC. | $104.50 | 2025 | |
| Deciphera Pharmaceuticals INC. | $24.13 | 2021 | |
| Genzyme Corporation | $21.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Brandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.